HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Genzyme

http://www.genzyme.com

Latest From Sanofi Genzyme

Seventeen And Counting – Bumper Crop Of New EU Filings

Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.

Europe Drug Review

Sanofi ‘Strongly Disagrees’ With EMA Rejection Of NAS Status For Nexviadyme

Sanofi argues that the European Medicines Agency applies a narrow interpretation of its new active substance principles which is not appropriate for biological therapies, and that the regulator fails to consider the challenges of conducting clinical research in rare diseases.

Europe Innovation

Rare EU Fast-Track Nod For Sanofi Genzyme's Olipudase Alfa

Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year. 

Europe Review Pathway

First-Of Kind BMS Drugs Among Myriad New Filings In EU

Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AnorMED
    • Bioenvision
    • ILEX Oncology, Inc.
    • Sangstat Medical Corporation
    • Genzyme Corporation
UsernamePublicRestriction

Register